Related Experiment Video

Updated: Sep 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

553

Identifying Potential Gene Defect Patterns Related to COVID-19 Based on Pharmacological and Bioinformatics Analysis

Hongqiang Lou1, Xusheng Li1, Suhua Gao1

  • 1Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua City, Zhejiang Province, 330700, People's Republic of China.

International Journal of General Medicine
|April 28, 2022
PubMed
Abstract

Insights

This study identified 26 COVID-19 target genes for lung adenocarcinoma (LUAD), with Interleukin-1beta (IL1B) as a key target for new drugs. Two molecular subtypes were found, potentially guiding personalized LUAD therapies.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Genomics

Background:

  • Coronavirus disease 2019 (COVID-19) poses significant risks to cancer patients, particularly those with lung cancer.
  • Lung adenocarcinoma (LUAD) patients are disproportionately affected by COVID-19, necessitating targeted therapeutic strategies.

Purpose of the Study:

  • To identify potential drug targets for lung adenocarcinoma (LUAD) patients co-infected with COVID-19.
  • To explore the relationship between COVID-19 related genes, traditional Chinese medicine (TCM) targets, and the tumor microenvironment (TME) in LUAD.

Main Methods:

  • Screened differentially expressed genes (DEGs) related to COVID-19 in LUAD samples from public databases.
  • Analyzed protein-protein interactions (PPI) of COVID-19 genes, TCM, and TCM targets using CytoScape.
  • Assessed correlations between TME and COVID-19 target genes, and performed unsupervised consensus clustering to define molecular subtypes.

Main Results:

  • Identified 26 COVID-19 target genes relevant to TCM for LUAD, with significant enrichment in Interleukin-17 and Tumor Necrosis Factor signaling pathways.
  • Found a strong correlation between COVID-19 target genes and TME, cell death, identifying Interleukin-1beta (IL1B) as a core gene in the PPI network.
  • Developed two distinct molecular subtypes based on the 26 target genes, demonstrating differences in overall survival, TME, and response to targeted therapy.

Conclusions:

  • The study identified 26 COVID-19 target genes as potential therapeutic targets for LUAD.
  • Interleukin-1beta (IL1B) was confirmed as a critical gene for developing novel molecular drugs.
  • Two novel molecular subtypes offer potential for guiding personalized treatment strategies in clinical practice for LUAD patients with COVID-19.
Keywords:
COVID-19drug targetslung adenocarcinomamolecular subtypestraditional Chinese medicinetumor microenvironment

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.1K